Park, Seung-Yoon Kim, In-San 2024-01-19T20:01:06Z 2024-01-19T20:01:06Z 2021-09-05 2019-06 0304-3835 https://pubs.kist.re.kr/handle/201004/119910 Myeloid lineage immune cells, such as macrophages and dendritic cells, play important roles in the induction of antitumor immunity during the initial stage of the cancer-immunity cycle, eliciting antitumor adaptive immunity by phagocytosing cancer cells and processing cancer-specific antigens, and then presenting these antigens to T cells. During this process, cancer cell phagocytosis can be prevented by inhibitory signals, and the signaling cascades that elicit immune responses against cancer antigens can be inhibited by immunosuppressive myeloid cells in the tumor microenvironment. A number of therapeutic strategies for enhancing cancer cell phagocytosis and promoting antitumor immunity by targeting myeloid lineage cells have recently been developed. Here, we discuss recent advances in cancer immunotherapy that involve the targeting of myeloid lineage immune cells to induce effective antitumor immunity. English ELSEVIER IRELAND LTD TUMOR-ASSOCIATED MACROPHAGES RHO-ASSOCIATED KINASE SUPPRESSOR-CELLS POOR-PROGNOSIS SIGNALING PROMOTES CD47 BLOCKADE T-CELLS INHIBITION RECEPTOR PHAGOCYTOSIS Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy Article 10.1016/j.canlet.2019.03.018 1 CANCER LETTERS, v.452, pp.51 - 58 CANCER LETTERS 452 51 58 scie scopus 000466454100005 2-s2.0-85063328555 Oncology Oncology Article TUMOR-ASSOCIATED MACROPHAGES RHO-ASSOCIATED KINASE SUPPRESSOR-CELLS POOR-PROGNOSIS SIGNALING PROMOTES CD47 BLOCKADE T-CELLS INHIBITION RECEPTOR PHAGOCYTOSIS Macrophages Dendritic cells Phagocytosis Antitumer immunity